336 related articles for article (PubMed ID: 15466638)
21. Role of activator protein-1 in the down-regulation of the human CYP2J2 gene in hypoxia.
Marden NY; Fiala-Beer E; Xiang SH; Murray M
Biochem J; 2003 Aug; 373(Pt 3):669-80. PubMed ID: 12737630
[TBL] [Abstract][Full Text] [Related]
22. A comprehensive study revealed SNP-SNP interactions and a sex-dependent relationship between polymorphisms of the CYP2J2 gene and hypertension risk.
Polonikov AV; Ponomarenko IV; Bykanova MA; Sirotina SS; Bocharova AV; Vagaytseva KV; Stepanov VA; Azarova IE; Churnosov MI; Solodilova MA
Hypertens Res; 2019 Feb; 42(2):257-272. PubMed ID: 30518987
[TBL] [Abstract][Full Text] [Related]
23. Determination of cytochrome P450 metabolites of arachidonic acid in coronary venous plasma during ischemia and reperfusion in dogs.
Nithipatikom K; DiCamelli RF; Kohler S; Gumina RJ; Falck JR; Campbell WB; Gross GJ
Anal Biochem; 2001 May; 292(1):115-24. PubMed ID: 11319825
[TBL] [Abstract][Full Text] [Related]
24. The common functional polymorphism -50G>T of the CYP2J2 gene is not associated with ischemic coronary and cerebrovascular events in an urban-based sample of Swedes.
Fava C; Montagnana M; Almgren P; Hedblad B; Engström G; Berglund G; Minuz P; Melander O
J Hypertens; 2010 Feb; 28(2):294-9. PubMed ID: 19851119
[TBL] [Abstract][Full Text] [Related]
25. CYP2J2 - regulation, function and polymorphism.
Murray M
Drug Metab Rev; 2016 Aug; 48(3):351-68. PubMed ID: 27286171
[TBL] [Abstract][Full Text] [Related]
26. CYP2J2 and EETs protect against lung ischemia/reperfusion injury via anti-inflammatory effects in vivo and in vitro.
Chen W; Yang S; Ping W; Fu X; Xu Q; Wang J
Cell Physiol Biochem; 2015; 35(5):2043-54. PubMed ID: 25870948
[TBL] [Abstract][Full Text] [Related]
27. Cytochrome P450 subfamily 2J polypeptide 2 expression and circulating epoxyeicosatrienoic metabolites in preeclampsia.
Herse F; Lamarca B; Hubel CA; Kaartokallio T; Lokki AI; Ekholm E; Laivuori H; Gauster M; Huppertz B; Sugulle M; Ryan MJ; Novotny S; Brewer J; Park JK; Kacik M; Hoyer J; Verlohren S; Wallukat G; Rothe M; Luft FC; Muller DN; Schunck WH; Staff AC; Dechend R
Circulation; 2012 Dec; 126(25):2990-9. PubMed ID: 23155181
[TBL] [Abstract][Full Text] [Related]
28. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes.
Wu S; Chen W; Murphy E; Gabel S; Tomer KB; Foley J; Steenbergen C; Falck JR; Moomaw CR; Zeldin DC
J Biol Chem; 1997 May; 272(19):12551-9. PubMed ID: 9139707
[TBL] [Abstract][Full Text] [Related]
29. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids.
Node K; Huo Y; Ruan X; Yang B; Spiecker M; Ley K; Zeldin DC; Liao JK
Science; 1999 Aug; 285(5431):1276-9. PubMed ID: 10455056
[TBL] [Abstract][Full Text] [Related]
30. Cytochrome p450 epoxygenase promotes human cancer metastasis.
Jiang JG; Ning YG; Chen C; Ma D; Liu ZJ; Yang S; Zhou J; Xiao X; Zhang XA; Edin ML; Card JW; Wang J; Zeldin DC; Wang DW
Cancer Res; 2007 Jul; 67(14):6665-74. PubMed ID: 17638876
[TBL] [Abstract][Full Text] [Related]
31. Cytochrome P450 2J2*7 polymorphisms in Japanese, Mongolians and Ovambos.
Takeshita H; Tsubota E; Takatsuka H; Kunito T; Fujihara J
Cell Biochem Funct; 2008 Oct; 26(7):813-6. PubMed ID: 18729130
[TBL] [Abstract][Full Text] [Related]
32. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases.
Zordoky BN; El-Kadi AO
Pharmacol Ther; 2010 Mar; 125(3):446-63. PubMed ID: 20093140
[TBL] [Abstract][Full Text] [Related]
33. Variability of CYP2J2 expression in human fetal tissues.
Gaedigk A; Baker DW; Totah RA; Gaedigk R; Pearce RE; Vyhlidal CA; Zeldin DC; Leeder JS
J Pharmacol Exp Ther; 2006 Nov; 319(2):523-32. PubMed ID: 16868033
[TBL] [Abstract][Full Text] [Related]
34. CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance.
Zeldin DC; Foley J; Ma J; Boyle JE; Pascual JM; Moomaw CR; Tomer KB; Steenbergen C; Wu S
Mol Pharmacol; 1996 Nov; 50(5):1111-7. PubMed ID: 8913342
[TBL] [Abstract][Full Text] [Related]
35. CYP4A11 polymorphism correlates with coronary endothelial dysfunction in patients with coronary artery disease--the ENCORE Trials.
Hermann M; Hellermann JP; Quitzau K; Hoffmann MM; Gasser T; Meinertz T; Münzel T; Fleming I; Lüscher TF
Atherosclerosis; 2009 Dec; 207(2):476-9. PubMed ID: 19615687
[TBL] [Abstract][Full Text] [Related]
36. Cytochrome P450 2J2 polymorphism in healthy Caucasians and those with diabetes mellitus.
Pucci L; Lucchesi D; Chirulli V; Penno G; Johansson I; Gervasi P; Del Prato S; Longo V
Am J Pharmacogenomics; 2003; 3(5):355-8. PubMed ID: 14575523
[TBL] [Abstract][Full Text] [Related]
37. The -50G>T polymorphism in the promoter of the CYP2J2 gene in coronary heart disease: the Ludwigshafen Risk and Cardiovascular Health study.
Hoffmann MM; Bugert P; Seelhorst U; Wellnitz B; Winkelmann BR; Boehm BO; März W
Clin Chem; 2007 Mar; 53(3):539-40. PubMed ID: 17327508
[No Abstract] [Full Text] [Related]
38. Genetic polymorphisms of the drug-metabolizing enzyme CYP2J2 in a Tibetan population.
Cao P; Zhao Q; Shao Y; Yang H; Jin T; Li B; Li H
Medicine (Baltimore); 2018 Oct; 97(40):e12579. PubMed ID: 30290621
[TBL] [Abstract][Full Text] [Related]
39. Meta-analysis of the association of the
Chen J; Wang DF; Fu GD; Ding J; Chen LY; Lv JL; Fang J; Yin X; Guo XG
Oncotarget; 2017 Aug; 8(35):59618-59627. PubMed ID: 28938665
[TBL] [Abstract][Full Text] [Related]
40. CYP2J2 overexpression attenuates nonalcoholic fatty liver disease induced by high-fat diet in mice.
Chen G; Xu R; Zhang S; Wang Y; Wang P; Edin ML; Zeldin DC; Wang DW
Am J Physiol Endocrinol Metab; 2015 Jan; 308(2):E97-E110. PubMed ID: 25389366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
